Glitact

Glitact is a prescription oral medication whose active ingredient is pioglitazone, a thiazolidinedione used for the management of type 2 diabetes mellitus. It is marketed in the European Union and is supplied as tablets (strength not specified). The drug works by activating PPAR‑γ receptors to improve insulin sensitivity and glucose utilization. It is intended for adult patients when diet, exercise, and other antidiabetic agents do not achieve adequate glycemic control.

Glitact is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive management plan.

- Used as monotherapy in patients who cannot tolerate metformin. - Added to existing metformin therapy to improve glycemic control. - Combined with other oral antidiabetic agents such as sulfonylureas or DPP‑4 inhibitors when additional glucose lowering is needed. - May be considered in patients with insulin resistance where improving insulin sensitivity is a therapeutic goal. - Prescribed alongside lifestyle interventions including diet modification and regular physical activity.

The safety profile of Glitact includes a range of adverse events that are reported with varying frequency.

Common: - Fluid retention that may present as mild peripheral edema, especially in the lower extremities. - Gradual weight gain, often associated with increased fluid volume. - Mild upper respiratory tract infections such as common cold symptoms. - Headache of varying intensity, usually transient. - Nausea or mild gastrointestinal discomfort, usually transient.

Serious: - Hepatotoxicity, indicated by significant elevations in liver transaminases (ALT/AST) and possible hepatitis. - Exacerbation of congestive heart failure, characterized by worsening dyspnea, edema, and reduced exercise tolerance. - Rare occurrences of bone fractures, particularly in patients with pre‑existing osteoporosis. - Severe hypoglycemia when combined with insulin or sulfonylureas.

When prescribing Glitact, clinicians should evaluate several precautionary factors to ensure safe use.

- Assess liver function before initiation and monitor periodically during therapy. - Use cautiously in patients with a history of heart failure or reduced ejection fraction. - Evaluate renal function, as dose adjustment may be required in severe impairment. - Consider the risk of bone loss in postmenopausal women or individuals with osteoporosis. - Review concomitant medications that may increase fluid retention or affect glucose levels. - Advise patients to report unexplained weight gain, swelling, or signs of liver injury promptly.

Glitact may interact with other medicines, influencing its efficacy or safety profile.

Avoid: - Concurrent use with potent CYP2C8 inhibitors (e.g., gemfibrozil) which can increase pioglitazone plasma concentrations. - Combination with insulin or sulfonylureas without dose adjustment, due to heightened risk of hypoglycemia. - Co‑administration with thiazide diuretics that may exacerbate fluid retention.

Use with caution: - Use with other thiazolidinediones is not recommended; additive effects on edema and heart failure risk. - Concomitant use of NSAIDs may increase the likelihood of renal impairment. - Combining with oral contraceptives may alter hormone levels; monitor for menstrual irregularities. - When used with warfarin, monitor INR more frequently as pioglitazone may affect anticoagulant control.